Ovarian Adenocarcinoma — Trials

Ovarian Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 83
Recruiting: 38
Ph III recruiting: 5
Growth YoY: —
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (25)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04575935	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial	recruiting	Phase 3	580	M.D. Anderson Cancer CenterOTHER	5	Sep 14, 2026	clinicaltrials
NCT05281471	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)	recruiting	Phase 3	186	Genelux CorporationINDUSTRY	1